Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma

  1. Lookup NU author(s)
  2. Dr David Hill
  3. Shaun Martin
  4. Dr Jane Armstrong
  5. Dr Ross Flockhart
  6. Dominic Simpson
  7. Professor Mark Birch-Machin
  8. Dr Christopher Redfern
  9. Dr Penny Lovat
Author(s)Hill DS, Martin S, Armstrong JL, Flockhart R, Tonison JJ, Simpson DG, Birch-Machin MA, Redfern CPF, Lovat PE
Publication type Article
JournalClinical Cancer Research
Year2009
Volume15
Issue4
Pages1192-1198
ISSN (print)1078-0432
ISSN (electronic)1557-3265
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
PURPOSE: Single-agent chemotherapy is largely the treatment of choice for systemic therapy of metastatic melanoma, but survival rates are low, and novel adjuvant and systemic therapies are urgently required. Endoplasmic reticulum (ER) stress is a potential therapeutic target, and two relatively new drugs, fenretinide and bortezomib (Velcade), each acting via different cellular mechanisms, induce ER stress leading to apoptosis in melanoma cells. The aim of this study was to test the hypothesis that apoptosis of melanoma cells may be increased by combining clinically achievable concentrations of fenretinide and bortezomib. EXPERIMENTAL DESIGN: Three human melanoma cell lines were used to assess changes in viability and the induction of apoptosis in response to fenretinide, bortezomib, or both drugs together. A s.c. xenograft model was used to test responses in vivo. RESULTS: Fenretinide and bortezomib synergistically decreased viability and increased apoptosis in all three melanoma lines at clinically achievable concentrations. This was also reflected by increased expression of GADD153, a marker of ER stress-induced apoptosis. In vivo, fenretinide in combination with bortezomib gave a marked reduction in xenograft tumor volume and an increase in apoptosis compared with fenretinide or bortezomib alone. The cell cycle stage of tumor cells in vivo were similar to that predicted from the effects of each drug or the combination in vitro. CONCLUSIONS: These results suggest that fenretinide and bortezomib, both of which are available in clinical formulation, warrant clinical evaluation as a combination therapy for metastatic melanoma.
PublisherAmerican Association for Cancer Research
URLhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2150
DOI10.1158/1078-0432.CCR-08-2150
PubMed id19228725
Actions    Link to this publication
Share